The legal action centers on the period between April 16, 2025, and May 4, 2026, during which GeneDx allegedly touted the Fabric Genomics unit as a primary driver of future profitability. Instead, the company’s first-quarter 2026 earnings revealed a sharp increase in net losses. The Fabric Genomics division missed revenue targets by $2.5 million, forcing the company to write off roughly 94% of the cash paid for the business just one year prior.

Beyond the impairment, GeneDx reported an unexpected shift in product mix toward lower-revenue genome offerings, causing annual recurring revenue to miss expectations. This forced a 12% reduction in 2026 revenue guidance. Reed Kathrein, the partner at Hagens Berman leading the investigation, questions whether executives were aware of the gap between their public growth narrative and the internal reality of their acquisitions. The firm is also examining the recent appointment of Mark Gardner as President to determine if the leadership change relates to the failures preceding the stock price decline. Investors have until August 3, 2026, to file for lead plaintiff status.